$1.35
+0.08 (+6.30%)
Open$1.30
Previous Close$1.27
Day High$1.41
Day Low$1.28
52W High$40.49
52W Low$25.27
Volume—
Avg Volume672.5K
Market Cap37.78M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,900.7% upside
Current
$1.35
$1.35
Target
$40.51
$40.51
$28.40
$40.51 avg
$50.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.30M | 6.48M | 4.92M |
| Net Income | -1,316,650 | -1,573,823 | -1,131,717 |
| Profit Margin | -20.9% | -24.3% | -23.0% |
| EBITDA | -2,363,922 | -2,326,744 | -1,866,701 |
| Free Cash Flow | -1,722,588 | -1,580,767 | -1,263,847 |
| Rev Growth | -2.8% | +6.4% | +0.2% |
| Debt/Equity | 0.17 | 0.14 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |